Outer membrane vesicle vaccines

Journal article : Review

Abstract:: Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps.

Files:: Micoli_and_MacLennan_2020_Outer_membrane_vesicle.pdf

(Preview, Accepted manuscript, pdf, 1.7MB, Terms of use)

Language:: English
Keywords:: outer membrane vesicles

bacterial diseases

OMV

GMMA

vaccines

FFR
Subtype:: Review
Pubs id:: 1179541
Local pid:: pubs:1179541
Deposit date:: 2021-10-08
ARK identifier:: ark:/29072/ora_12cad63c02da42deadb4f7f6fcedd51d

Notes:: This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.smim.2020.101433

If you are the owner of this record, you can report an update to it here: Report update to this record